Lower gastrointestinal tract cancer predisposition syndromes

Hematology/Oncology Clinics of North America

Volumn 24, Issue 6, 2010, Pages 1229-1252

  Shah, Neel B ^a   Lindor, Noralane M ^a  

^a MAYO CLINIC   (United States)

Author keywords

Cancer; Colorectal; Genetic syndrome; Lower GI; Risk

Indexed keywords

BONE MORPHOGENETIC PROTEIN RECEPTOR 1A; DNA GLYCOSYLASE MUTY; PROTEIN KINASE LKB1; SMAD4 PROTEIN;

ADENOMATOUS POLYP; CANCER RISK; CANCER SCREENING; CANCER SURGERY; CANCER SUSCEPTIBILITY; DIGESTIVE SYSTEM CANCER; GENE MUTATION; GENETIC ASSOCIATION; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HUMAN; JUVENILE POLYPOSIS; MORBIDITY; PEUTZ JEGHERS SYNDROME; POLYPOSIS; PRIORITY JOURNAL; RENDU OSLER WEBER DISEASE; REVIEW;

ADENOMATOUS POLYPOSIS COLI; COLORECTAL NEOPLASMS, HEREDITARY NONPOLYPOSIS; GASTROINTESTINAL NEOPLASMS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INTESTINAL POLYPOSIS; MUTATION; PEUTZ-JEGHERS SYNDROME; RISK FACTORS; SYNDROME;

EID: 78249232944     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hoc.2010.08.012     Document Type: Review

References (179)

1. Amos C., Keitheri-Cheteri M., Sabripour M., et al. Genotype-phenotype correlations in Peutz-Jegher syndrome. J Med Genet 2004, 41(5):327-333.
2. Boardman L. Heritable colorectal cancer syndromes: recognition and preventive management. Gastroenterol Clin North Am 2002, 31:1107-1131.
3. Anyanwu S. Sporadic Peutz-Jeghers syndrome in a Nigerian. Cent Afr J Med 1999, 45(7):182-184.
4. Yoon K., Ku J., Choi H., et al. Germline mutations of the STK11 gene in Korean Peutz-Jeghers syndrome patients. Br J Cancer 2000, 82(8):1403-1406.
5. Riegert-Johnson D., Boardman L. Peutz-Jeghers syndrome. Genetics of colorectal cancer 2009, 193-198. Springer, New York. J. Potter, N. Lindor (Eds.).
6. Hearle N., Schumacher V., Menko F., et al. Frequency and spectrum of cancers in the Peutz-Jeghers syndrome. Cancer Res 2006, 12(10):3209-3215.
7. Mehenni H., Resta N., Park J., et al. Cancer risks in LKB1 germline mutation carriers. Gut 2006, 55(7):984-990.
8. Olschwang S., Boisson C., Thomas G. Peutz-Jeghers families unlinked to STK11/LKB1 gene mutations are highly predisposed to primitive biliary adenocarcinoma. J Med Genet 2001, 38(6):356-360.
9. Aaltonen L. Peutz-Jeghers syndrome. The genetic basis of human cancer 2002, 337-341. McGraw-Hill, New York. B. Vogelstein, K. Kinzler (Eds.).
10. Hemminki A., Markie D., Tomlinson I., et al. A serine/threonine kinase gene defective in Peutz-Jeghers syndrome. Nature 1998, 391(6663):184-187.
11. Jenne D., Reimann H., Nezu J., et al. Peutz-Jeghers syndrome is caused by mutations in a novel serine threonine kinase. Nat Genet 1998, 18:38-43.
12. Giardiello F., Hamilton S., Kern S., et al. Colorectal neoplasia in juvenile polyposis or juvenile polyps. Arch Dis Child 1991, 66(8):971-975.
13. Rowan A., Churchman M., Jefferey R., et al. In situ analysis of LKB1/STK11 mRNA expression in human normal tissues and tumours. J Pathol 2000, 192(2):203-206.
14. Boudeau J., Baas A., Deak M., et al. MO25alpha/beta interact with STRAD alpha/beta enhancing their ability to bind, activate and localize LKB1 in the cytoplasm. EMBO J 2003, 22(19):5102-5114.
15. Ylikorkala A., Avizienyte E., Tomlinson I., et al. Mutations and impaired function of LKB1 in familial and non-familial Peutz-Jeghers syndrome and sporadic testicular cancer. Hum Mol Genet 1999, 8:45-51.
16. Karuman P., Gozani O., Odze R., et al. The Peutz-Jegher gene product LKB1 is a mediator of p53-dependent cell death. Mol Cell 2001, 7:1307-1319.
17. Gruber S., Entius M., Petersen G., et al. Pathogenesis of adenocarcinoma in Peutz-Jeghers syndrome. Cancer Res 1998, 58:5267-5270.
18. Flageole H., Raptis S., Trudel J., et al. Progression toward malignancy of hamartomas in a patient with Peutz-Jeghers syndrome: case report and literature. Can J Surg 1994, 37(3):231-236.
19. Nakau M., Miyoshi H., Seldin M., et al. Hepatocellular carcinoma caused by loss of heterozygosity in LKB1 gene knockout mice. Cancer Res 2002, 62:4549-4553.
20. Jishage K., Nezu J., Kawase Y., et al. Role of Lkb1, the causative gene of Peutz-Jegher's syndrome, in embryogenesis and polyposis. Proc Natl Acad Sci U S A 2002, 99(13):8903-8908.
21. Amos C, Frazier M, McGarrity T. Peutz-Jeghers syndrome. In: GeneReviews at GeneTests: Medical Genetics Information Resource (database online) Gene reviews 2009, (Updated May 15 2007). Copyright, University of Washington, Seattle 1997-2010. Available at: Accessed November 30, 2009. http://www.genetests.org.
22. Hinds R., Philp C., Hyer W., et al. Complications of childhood Peutz-Jeghers syndrome: implications for pediatric screening. J Pediatr Gastroenterol Nutr 2004, 39:219-220.
23. Pennazio M., Rossini F. Small bowel polyps in Peutz-Jeghers syndrome: management by combined push enteroscopy and intra-operative enteroscopy. Gastrointest Endosc 2000, 51(3):304-308.
24. Edwards D., Khosraviani K., Stafferton R., et al. Long-term results of polyp clearance by intra-operative enteroscopy in the Peutz-Jeghers syndrome. Dis Colon Rectum 2003, 46(1):48-50.
25. Aaltonen L., Jass J., Howe J. Juvenile polyposis. Pathology and genetics. Tumours of the digestive system. Lyon (France) 2000, 130-132. IARC Press. S. Hamilton, L. Aaltonen (Eds.).
26. Burt R., Bishop D., Lynch H., et al. Risk and surveillance of individuals with heritable factors for colorectal cancer. WHO Collaborating Centre for the Prevention of Colorectal Cancer. Bull World Health Organ 1990, 68(5):655-665.
27. Nugent K., Talbot I., Hodgson S., et al. Solitary juvenile polyps: not a marker for subsequent malignancy. Gastroenterology 1993, 105(3):698-700.
28. Brosens L., van Hattem A., Hylind L., et al. Risk of colorectal cancer in juvenile polyposis. Gut 2007, 56(7):965-967.
29. Hofting I., Pott G., Stolte M. The syndrome of juvenile polyposis. Leber Magen Darm 1993, 23:111-112.
30. Chow E., Macrae F. A review of juvenile polyposis syndrome. J Gastroenterol Hepatol 2005, 20(11):1634-1640.
31. Brosens L., van Hattem W., Jansen M., et al. Gastrointestinal polyposis syndromes. Curr Mol Med 2007, 7(1):29-46.
32. Howe J., Sayed M., Ahmed A., et al. The prevalence of MADH4 and BMPR1A mutations in juvenile polyposis and absence of BMPR2, BMPR1B, and ACVR1 mutations. J Med Genet 2004, 41(7):484-491.
33. Merg A., Lynch H., Lynch J., et al. Hereditary colorectal cancer-part II. Curr Probl Surg 2005, 42(5):267-333.
34. Roth S., Sistonen P., Salovaara R., et al. SMAD genes in juvenile polyposis. Genes Chromosomes Cancer 1999, 26(1):54-61.
35. Sayed M., Ahmed A., Ringold J., et al. Germline SMAD4 or BMPR1A mutations and phenotype of juvenile polyposis. Ann Surg Oncol 2002, 9(9):901-906.
36. Pyatt R., Pilarski R., Prior T. Mutation screening in juvenile polyposis syndrome. J Mol Diagn 2006, 8(1):84-88.
37. Kim B., Li C., Qiao W., et al. SMAD4 signalling in T cells is required for suppression of gastrointestinal cancer. Nature 2006, 441(7096):1015-1019.
38. Kinzler K., Vogelstein B. Landscaping the cancer terrain. Science 1998, 280(5366):1036-1037.
39. Friedl W., Uhlhaas S., Schulmann K., et al. Juvenile polyposis: massive gastric polyposis is more common in MADH4 mutation carriers than in BMPR1A mutation carriers. Hum Genet 2002, 111(1):108-111.
40. Handra-Luca A., Condroyer C., de Moncuit C., et al. Vessels' morphology in SMAD4 and BMPR1A-related juvenile polyposis. Am J Med Genet 2005, 138(2):113-117.
41. Sweet K., Willis J., Zhou X., et al. Molecular classification of patients with unexplained hamartomatous and hyperplastic polyposis. JAMA 2005, 294(19):2465-2473.
42. Blanco F., Santibanez J., Guerrero-Esteo M., et al. Interaction and functional interplay between endoglin and ALK-1, two components of the endothelial transforming growth factor-beta receptor complex. J Cell Physiol 2005, 204(2):574-584.
43. Howe J., Haidle J., Lal G., et al. ENG mutations in MADH4/BMPR1A mutation negative patients with juvenile polyposis. Clin Genet 2007, 71(1):91-92.
44. Howe J., Mitros F., Summers R. The risk of gastrointestinal carcinoma in familial juvenile polyposis. Ann Surg Oncol 1998, 5(8):751-756.
45. Galiatsatos P., Foulkes W. Familial adenomatous polyposis. Am J Gastroenterol 2006, 101(2):385-398.
46. Rozen P., Macrae F. Familial adenomatous polyposis: the practical applications of clinical and molecular screening. Fam Cancer 2006, 5(3):227-235.
47. Lipton L., Tomlinson I. The genetics of FAP and FAP-like syndrome. Fam Cancer 2006, 5:221-226.
48. Guillem J., Smith A., Calle J., et al. Gastrointestinal polyposis syndromes. Curr Probl Surg 1999, 36(4):217-323.
49. Lockhart-Mummery P. Cancer and heredity. Lancet 1925, 205(5296):427-429.
50. Houlston R., Crabtree M., Phillips R., et al. Explaining differences in the severity of familial adenomatous polyposis and the search for modifier genes. Gut 2001, 48(1):1-5.
51. Lal G., Gallinger S. Familial adenomatous polyposis. Semin Surg Oncol 2000, 18(4):314-323.
52. Hamilton S., Liu B., Parsons R., et al. The molecular basis of Turcot's syndrome. N Engl J Med 1995, 332(13):839-847.
53. Zippel D., Temple W. When is a neoplasm not a neoplasm? When it is a desmoid. J Surg Oncol 2007, 95(3):190-191.
54. Sturt N., Clark S. Current ideas in desmoid tumours. Fam Cancer 2006, 5(3):275-285.
55. Bertario L., Russo A., Sala P., et al. Genotype and phenotype factors as determinants of desmoid tumors in patients with familial adenomatous polyposis. Int J Cancer 2001, 95(2):102-107.
56. Lynch H., Fitzgibbons R. Surgery, desmoid tumors, and familial adenomatous polyposis: case report and literature review. Am J Gastroenterol 1996, 91(12):2598-2601.
57. Eccles D., van der Luijt R., Breukel C., et al. Hereditary desmoid disease due to a frameshift mutation at codon 1924 of the APC gene. Am J Hum Genet 1996, 59(6):1193-1201.
58. Chen C., Phillips K., Grist S., et al. Congenital hypertrophy of the retinal pigment epithelium (CHRPE) in familial colorectal cancer. Fam Cancer 2006, 5(4):397-404.
59. Knudsen A., Bisgaard M., Bülow S. Attenuated familial adenomatous polyposis (AFAP). A review of the literature. Fam Cancer 2003, 2(1):43-55.
60. Brensinger J., Laken S., Luce M., et al. Variable phenotype of familial adenomatous polyposis in pedigrees with 3' mutation in the APC gene. Gut 1998, 43(4):548-552.
61. Sieber O., Segditsas S., Knudsen A., et al. Disease severity and genetic pathways in attenuated FAP vary greatly but depend on the site of the germline mutation. Gut 2006, 55(10):1440-1448.
62. Nieuwenhuis M., Vasen H. Correlations between mutation site in APC and phenotype of familial adenomatous polyposis (FAP): a review of the literature. Crit Rev Oncol Hematol 2007, 61(2):153-161.
63. Lefevre J., Parc Y., Svrcek M., et al. APC, MYH, and the correlation genotype-phenotype in colorectal polyposis. Ann Surg Oncol 2009, 16(4):871-877.
64. Berk T., Cohen Z., Bapat B., et al. Negative genetic test results in familial adenomatous polyposis: clinical screening implications. Dis Colon Rectum 1999, 42(3):307-310.
65. Petersen G., Slack J., Nakamura Y. Screening guidelines and premorbid diagnosis of familial adenomatous polyposis using linkage. Gastroenterology 1991, 100(6):1658-1664.
66. Rustin R., Jagelman D., McGannon E., et al. Spontaneous mutation in familial adenomatous polyposis. Dis Colon Rectum 1990, 33(1):52-55.
67. Arvanitis M., Jagelman D., Fazio V., et al. Mortality in patients with familial adenomatous polyposis. Dis Colon Rectum 1990, 33(8):639-642.
68. Church J., McGannon E., Hull-Boiner S., et al. Gastroduodenal polyps in patients with familial adenomatous polyposis. Dis Colon Rectum 1992, 35:1170-1173.
69. Kadmon M., Tandara A., Herfarth C. Duodenal adenomatosis in familial adenomatous polyposis coli. A review of the literature and results from the Heidelberg Polyposis Register. Int J Colorectal Dis 2001, 16(2):63-75.
70. Groves C., Saunders B., Spigelman A., et al. Duodenal cancer in patients with familial adenomatous polyposis (FAP): results of a 10 year prospective study. Gut 2002, 50(5):636-641.
71. Park J., Park K., Ahn Y., et al. Risk of gastric cancer among Korean familial adenomatous polyposis patients. Report of three cases. Dis Colon Rectum 1992, 35(10):996-998.
72. Brosens L., Keller J., Offerhaus G., et al. Prevention and management of duodenal polyps in familial adenomatous polyposis. Gut 2005, 54(7):1034-1043.
73. Cetta F., Mazzarella L., Bon G., et al. Genetic alterations in hepatoblastoma and hepatocellular carcinoma associated with familial adenomatous polyposis. Med Pediatr Oncol 2003, 41(5):496-497.
74. Herraiz M., Barbesino G., Faquin W., et al. Prevalence of thyroid cancer in familial adenomatous polyposis syndrome and the role of screening ultrasound examinations. Clin Gastroenterol Hepatol 2007, 5(3):367-373.
75. Fearnhead N., Britton M., Bodmer W. The ABC of APC. Hum Mol Genet 2001, 10(7):721-733.
76. Näthke I. The adenomatous polyposis coli protein: the Achilles heel of the gut epithelium. Annu Rev Cell Dev Biol 2004, 20:337-366.
77. Bertario L., Russo A., Sala P., et al. Multiple approach to the exploration of genotype-phenotype correlations in familial adenomatous polyposis. J Clin Oncol 2003, 21(9):1698-1707.
78. Caspari R., Olschwang S., Friedl W., et al. Familial adenomatous polyposis: desmoid tumours and lack of ophthalmic lesions (CHRPE) associated with APC mutations beyond codon 1444. Hum Mol Genet 1995, 4(3):337-340.
79. Enomoto M., Konishi M., Iwama T., et al. The relationship between frequencies of extracolonic manifestations and the position of APC germline mutation in patients with familial adenomatous polyposis. Jpn J Clin Oncol 2000, 30(2):82-88.
80. Ficari F., Cama A., Valanzano R., et al. APC gene mutations and colorectal adenomatosis in familial adenomatous polyposis. Br J Cancer 2000, 82:348-353.
81. Kashiwagi H., Spigelman A. Gastroduodenal lesions in familial adenomatous polyposis. Surg Today 2000, 30:675-682.
82. Ferenc T., Sygut J., Kopczyński J., et al. Aggressive fibromatosis (desmoid tumors): definition, occurrence, pathology, diagnostic problems, clinical behavior, genetic background. Pol J Pathol 2006, 57(1):5-15.
83. Durno C., Monga N., Bapat B., et al. Does early colectomy increase desmoid risk in familial adenomatous polyposis?. Clin Gastroenterol Hepatol 2007, 5(10):1190-1194.
84. Nielsen M., Joerink-van de Beld M., Jones N., et al. Analysis of MUTYH genotypes and colorectal phenotypes in patients With MUTYH-associated polyposis. Gastroenterology 2009, 136(2):471-476.
85. Jones N., Vogt S., Nielsen M., et al. Increased colorectal cancer incidence in obligate carriers of heterozygous mutations in MUTYH. Gastroenterology 2009, 137(2):489-494.
86. Gruber S., Kohlmann W. The genetics of hereditary non-polyposis colorectal cancer. J Natl Compr Canc Netw 2003, 1(1):137-144.
87. Rhyu M. Molecular mechanisms underlying hereditary nonpolyposis colorectal carcinoma. J Natl Cancer Inst 1996, 88(5):240-251.
88. Chung D., Rustgi A. DNA mismatch repair and cancer. Gastroenterology 1995, 109(5):1685-1699.
89. Lazar V., Grandjouan S., Bognel C., et al. Accumulation of multiple mutations in tumour suppressor genes during colorectal tumorigenesis in HNPCC patients. Hum Mol Genet 1994, 3(12):2257-2260.
90. Hampel H., Frankel W., Martin E., et al. Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer). N Engl J Med 2005, 352(18):1851-1860.
91. Wijnen J., Vasen H., Khan P., et al. Clinical findings with implications for genetic testing in families with clustering of colorectal cancer. N Engl J Med 1998, 339(8):511-518.
92. Hampel H., Frankel W., Panescu J., et al. Screening for Lynch syndrome (hereditary nonpolyposis colorectal cancer) among endometrial cancer patients. Cancer Res 2006, 66(15):7810-7817.
93. Watson P., Lynch H. Extracolonic cancer in hereditary nonpolyposis colorectal cancer. Cancer 1993, 71(3):677-685.
94. Watson P., Vasen H., Mecklin J., et al. The risk of endometrial cancer in hereditary nonpolyposis colorectal cancer. Am J Med 1994, 96(6):516-520.
95. Aarnio M., Mecklin J., Aaltonen L., et al. Life-time risk of different cancers in hereditary non-polyposis colorectal cancer (HNPCC) syndrome. Int J Cancer 1995, 64(6):430-433.
96. Kastrinos F., Mukherjee B., Tayob N., et al. Risk of pancreatic cancer in families with Lynch syndrome. JAMA 2009, 302(16):1790-1795.
97. Suspiro A., Fidalgo P., Cravo M., et al. The Muir-Torre syndrome: a rare variant of hereditary nonpolyposis colorectal cancer associated with hMSH2 mutation. Am J Gastroenterol 1998, 93(9):1572-1574.
98. Kruse R., Rütten A., Lamberti C., et al. Muir-Torre phenotype has a frequency of DNA mismatch-repair-gene mutations similar to that in hereditary nonpolyposis colorectal cancer families defined by the Amsterdam criteria. Am J Hum Genet 1998, 63(1):63-70.
99. South C., Hampel H., Comeras I., et al. The frequency of Muir-Torre syndrome among Lynch syndrome families. J Natl Cancer Inst 2008, 100(4):277-281.
100. Vasen H., Mecklin J., Khan P., et al. The International Collaborative Group on hereditary nonpolyposis colorectal cancer (ICG-HNPCC). Dis Colon Rectum 1991, 34(5):424.
101. Syngal S., Fox E., Li C., et al. Interpretation of genetic test results for hereditary nonpolyposis colorectal cancer: implications for clinical predisposition testing. JAMA 1999, 282(3):247-253.
102. Liu B., Parsons R., Papadopoulos N., et al. Analysis of mismatch repair genes in hereditary non-polyposis colorectal cancer patients. Nat Med 1996, 2(2):169-174.
103. Beck N., Tomlinson I., Homfray T., et al. Genetic testing is important in families with a history suggestive of hereditary non-polyposis colorectal cancer even if the Amsterdam criteria are not fulfilled. Br J Surg 1997, 84(2):233-237.
104. Vasen H., Watson P., Mecklin J., et al. New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC. Gastroenterology 1999, 116(6):1453-1456.
105. Umar A., Boland C., Terdiman J., et al. Revised Bethesda guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst 2004, 96(4):261-268.
106. Lindor N., Rabe K., Petersen G., et al. Lower cancer incidence in Amsterdam-I criteria families without mismatch repair deficiency: familial colorectal cancer type X. JAMA 2005, 293(16):1979-1985.
107. Mueller-Koch Y., Vogelsang H., Kopp R., et al. Hereditary non-polyposis colorectal cancer: clinical and molecular evidence for a new entity of hereditary colorectal cancer. Gut 2005, 2005(54):12.
108. Llor X., Pons E., Xicola R., et al. Differential features of colorectal cancers fulfilling Amsterdam criteria without involvement of the mutator pathway. Clin Cancer Res 2005, 11(20):7304-7310.
109. Valle L., Perea J., Carbonell P., et al. Clinicopathologic and pedigree differences in Amsterdam I-positive hereditary nonpolyposis colorectal cancer families according to tumor microsatellite instability status. J Clin Oncol 2007, 25(7):781-786.
110. Jass J. Hereditary non-polyposis colorectal cancer: the rise and fall of a confusing term. World J Gastroenterol 2006, 12(31):4943-4950.
111. Abdel-Rahman W., Ollikainen M., Kariola R., et al. Comprehensive characterization of HNPCC-related colorectal cancers reveals striking molecular features in families with no germline mismatch repair gene mutations. Oncogene 2005, 24:1542-1551.
112. Vasen H., Möslein G., Alonso A., et al. Guidelines for the clinical management of Lynch syndrome (hereditary non-polyposis cancer). J Med Genet 2007, 44(6):353-362.
113. Hendriks Y., Wagner A., Morreau H., et al. Cancer risk in hereditary nonpolyposis colorectal cancer due to MSH6 mutations: impact on counseling and surveillance. Gastroenterology 2004, 127(1):17-25.
114. Piñol V., Castells A., Andreu M., et al. Accuracy of revised Bethesda guidelines, microsatellite instability, and immunohistochemistry for the identification of patients with hereditary nonpolyposis colorectal cancer. JAMA 2005, 293(16):1986-1994.
115. Choi Y., Cotterchio M., McKeown-Eyssen G., et al. Penetrance of colorectal cancer among MLH1/MSH2 carriers participating in the colorectal cancer familial registry in Ontario. Hered Cancer Clin Pract 2009, 7(1):14.
116. Lagerstedt-Robinson K., Liu T., Vandrovcova J., et al. Lynch syndrome (hereditary nonpolyposis colorectal cancer) diagnostics. J Natl Cancer Inst 2007, 99(4):291-299.
117. Broaddus R., Lynch H., Chen L., et al. Pathologic features of endometrial carcinoma associated with HNPCC: a comparison with sporadic endometrial carcinoma. Cancer 2006, 106(1):87-94.
118. Weber J., May P. Abundant class of human DNA polymorphisms which can be typed using the polymerase chain reaction. Am J Hum Genet 1989, 44(3):388-396.
119. Aaltonen A., Peltomäki P., Leach F., et al. Clues to the pathogenesis of familial colorectal cancer. Science 1993, 260(5109):812-816.
120. Boland C., Thibodeau S., Hamilton S., et al. A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res 1998, 58(22):5248-5257.
121. Cunningham J., Kim C., Christensen E., et al. The frequency of hereditary defective mismatch repair in a prospective series of unselected colorectal carcinomas. Am J Hum Genet 2001, 69:780-790.
122. Thibodeau S., French A., Roche P., et al. Altered expression of hMSH2 and hMLH1 in tumors with microsatellite instability and genetic alterations in mismatch repair genes. Cancer Res 1996, 56(21):4836-4840.
123. Cawkwell L., Gray S., Murgatroyd H., et al. Choice of management strategy for colorectal cancer based on a diagnostic immunohistochemical test for defective mismatch repair. Gut 1999, 45(3):409-415.
124. de La Chapelle A. Microsatellite instability phenotype of tumors: genotyping or immunohistochemistry? The jury is still out. J Clin Oncol 2002, 20(4):897-899.
125. Lindor N., Burgart L., Leontovich O., et al. Immunohistochemistry versus microsatellite instability testing in phenotyping colorectal tumors. J Clin Oncol 2002, 20(4):1043-1048.
126. Rigau V., Sebbagh N., Olschwang S., et al. Microsatellite instability in colorectal carcinoma. The comparison of immunohistochemistry and molecular biology suggests a role for hMSH6 [correction of hMLH6] immunostaining. Arch Pathol Lab Med 2003, 127(6):694-700.
127. Kievit W., de Bruin J., Adang E., et al. Current clinical selection strategies for identification of hereditary non-polyposis colorectal cancer families are inadequate: a meta-analysis. Clin Genet 2004, 65(4):308-316.
128. Southey M., Jenkins M., Mead L., et al. Use of molecular tumor characteristics to prioritize mismatch repair gene testing in early-onset colorectal cancer. J Clin Oncol 2005, 23(27):6524-6532.
129. Baudhuin L., Burgart L., Leontovich O., et al. Use of microsatellite instability and immunohistochemistry testing for the identification of individuals at risk for Lynch syndrome. Fam Cancer 2005, 4(3):255-265.
130. Marra G., Boland C. Hereditary nonpolyposis colorectal cancer: the syndrome, the genes, and historical perspectives. J Natl Cancer Inst 1995, 87(15):1114-1125.
131. Peltomäki P., Vasen H. Mutations predisposing to hereditary nonpolyposis colorectal cancer: database and results of a collaborative study. The International Collaborative Group on Hereditary Nonpolyposis Colorectal Cancer. Gastroenterology 1997, 113(4):1146-1158.
132. Charbonnier F., Olschwang S., Wang Q., et al. MSH2 in contrast to MLH1 and MSH6 is frequently inactivated by exonic and promoter rearrangements in hereditary nonpolyposis colorectal cancer. Cancer Res 2002, 62(3):848-853.
133. Wagner A., Barrows A., Wijnen J., et al. Molecular analysis of hereditary nonpolyposis colorectal cancer in the United States: high mutation detection rate among clinically selected families and characterization of an American founder genomic deletion of the MSH2 gene. Am J Hum Genet 2003, 72(5):1088-1100.
134. Wang Y., Friedl W., Lamberti C., et al. Hereditary nonpolyposis colorectal cancer: frequent occurrence of large genomic deletions in MSH2 and MLH1 genes. Int J Cancer 2003, 103(5):636-641.
135. Burke W., Petersen G., Lynch P., et al. Recommendations for follow-up care of individuals with an inherited predisposition to cancer. I. Hereditary nonpolyposis colon cancer. Cancer Genetics Studies Consortium. JAMA 1997, 277(11):915-919.
136. Lindor N., Petersen G., Hadley D., et al. Recommendations for the care of individuals with an inherited predisposition to Lynch syndrome: a systematic review. JAMA 2006, 296(12):1507-1517.
137. Reitmair A., Cai J., Bjerknes M., et al. MSH2 deficiency contributes to accelerated APC-mediated intestinal tumorigenesis. Cancer Res 1996, 56(13):2922-2926.
138. Järvinen H., Aarnio M., Mustonen H., et al. Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer. Gastroenterology 2000, 118(5):829-834.
139. Renkonen-Sinisalo L., Kivisaari A., Kivisaari L., et al. Utility of computed tomographic colonography in surveillance for hereditary nonpolyposis colorectal cancer syndrome. Fam Cancer 2007, 6(1):135-140.
140. Hurlstone D., Karajeh M., Cross S., et al. The role of high-magnification-chromoscopic colonoscopy in hereditary nonpolyposis colorectal cancer screening: a prospective " back-to-back" endoscopic study. Am J Gastroenterol 2005, 100(10):2167-2173.
141. Lecomte T., Cellier C., Meatchi T., et al. Chromoendoscopic colonoscopy for detecting preneoplastic lesions in hereditary nonpolyposis colorectal cancer syndrome. Clin Gastroenterol Hepatol 2005, 3(9):897-902.
142. Rodríguez-Bigas M., Vasen H., Pekka-Mecklin J., et al. Rectal cancer risk in hereditary nonpolyposis colorectal cancer after abdominal colectomy. International Collaborative Group on HNPCC. Ann Surg 1997, 225(2):202-207.
143. Ng A., Reagan J., Hawliczek S., et al. Significance of endometrial cells in the detection of endometrial carcinoma and its precursors. Acta Cytol 1974, 18(5):356-361.
144. Yancey M., Magelssen D., Demaurez A., et al. Classification of endometrial cells on cervical cytology. Obstet Gynecol 1990, 76(6):1000-1005.
145. Dove-Edwin I., Boks D., Goff S., et al. The outcome of endometrial carcinoma surveillance by ultrasound scan in women at risk of hereditary nonpolyposis colorectal carcinoma and familial colorectal carcinoma. Cancer 2002, 94(6):1708-1712.
146. Rijcken F., Mourits M., Kleibeuker J., et al. Gynecologic screening in hereditary nonpolyposis colorectal cancer. Gynecol Oncol 2003, 91(1):74-80.
147. Renkonen-Sinisalo L., Bützow R., Leminen A., et al. Surveillance for endometrial cancer in hereditary nonpolyposis colorectal cancer syndrome. Int J Cancer 2007, 120(4):821-824.
148. Schmeler K., Lynch H., Chen L., et al. Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome. N Engl J Med 2006, 354(3):261-269.
149. Felton K., Gilchrist D., Andrew S. Constitutive deficiency in DNA mismatch repair. Clin Genet 2007, 71(6):483-498.
150. Lucci-Cordisco E., Zito I., Gensini F., et al. Hereditary nonpolyposis colorectal cancer and related conditions. Am J Med Genet 2003, 122(4):325-334.
151. Al-Tassan N., Chmiel N., Maynard J., et al. Inherited variants of MYH associated with somatic G: C->T: A mutations in colorectal tumors. Nat Genet 2002, 30(2):227-232.
152. Sampson J., Dolwani S., Jones S., et al. Autosomal recessive colorectal adenomatous polyposis due to inherited mutations of MYH. Lancet 2003, 362(9377):39-41.
153. Sieber O., Lipton L., Crabtree M., et al. Multiple colorectal adenomas, classic adenomatous polyposis, and germ-line mutations in MYH. N Engl J Med 2003, 348(9):791-799.
154. Jenkins M., Croitoru M., Monga N., et al. Risk of colorectal cancer in monoallelic and biallelic carriers of MYH Mutations: a population-based case-family study. Cancer Epidemiol Biomarkers Prev 2006, 15(2):312-314.
155. Croitoru M., Cleary S., Di Nicola N., et al. Association between biallelic and monoallelic germline MYH gene mutations and colorectal cancer risk. J Natl Cancer Inst 2004, 96(21):1631-1634.
156. Farrington S., Tenesa A., Barnetson R., et al. Germline susceptibility to colorectal cancer due to base-excision repair gene defects. Am J Med Genet 2005, 77(1):112-119.
157. Webb E., Rudd M., Houlston R. Colorectal cancer risk in monoallelic carriers of MYH variants. Am J Med Genet 2006, 79(4):768-771.
158. Lubbe S., Di Bernardo M., Chandler I., et al. Clinical implications of the colorectal cancer risk associated with MUTYH mutation. J Clin Oncol 2009, 27(24):3975-3980.
159. Avezzù A., Agostini M., Pucciarelli S., et al. The role of MYH gene in genetic predisposition to colorectal cancer: another piece of the puzzle. Cancer Lett 2008, 268(2):308-313.
160. Nielsen M., Franken P., Reinards T., et al. Multiplicity in polyp count and extracolonic manifestations in 40 Dutch patients with MYH associated polyposis coli (MAP). J Med Genet 2005, 42(9):e54.
161. Nielsen M., Poley J., Verhoef S., et al. Duodenal carcinoma in MUTYH-associated polyposis. J Clin Pathol 2006, 59(11):1212-1215.
162. Lipton L., Tomlinson I. The multiple colorectal adenoma phenotype and MYH, a base excision repair gene. Clin Gastroenterol Hepatol 2004, 2(8):633-638.
163. Holter S., Gallinger S. MUTYH-associated polyposis. Genetics of colorectal cancer 2009, Springer Science Business Media, New York, p. 173--81. J. Potter, N. Lindor (Eds.).
164. Cheadle J., Sampson J. MUTYH-associated polyposis-from defect in base excision repair to clinical genetic testing. DNA Repair (Amst) 2007, 6:274-279.
165. Halford S., Rowan A., Lipton L., et al. Germline mutations but not somatic changes at the MYH locus contribute to the pathogenesis of unselected colorectal cancers. Am J Pathol 2003, 162(5):1545-1548.
166. Okamoto K., Toyokuni S., Uchida K., et al. Formation of 8-hydroxy-2'-deosyguanosine and 4-hydroxy-2-nonenal-modified proteins in human renal-cell carcinoma. Int J Cancer 1994, 58(6):824-829.
167. Malins D., Haimanot R. Major alterations in the nucleotide structure of DNA in cancer of the female breast. Cancer Res 1991, 51(19):5430-5432.
168. Jaruga P., Zastawny T., Skokowski J., et al. Oxidative DNA base damage and antioxidant enzyme activities in human lung cancer. FEBS Lett 1994, 341(1):59-64.
169. DeMarzo A., Nelson W., Isaacs W., et al. Pathological and molecular aspects of prostate cancer. Lancet 2003, 361(9361):955-964.
170. Giardiello F., Offerhaus J. Phenotype and cancer risk of various polyposis syndromes. Eur J Cancer 1995, 31A(7-8):1085-1087.
171. Jagelman D., DeCosse J., Bussey H. Upper gastrointestinal cancer in familial adenomatous polyposis. Lancet 1988, 1(8595):1149-1151.
172. Sturt N., Gallagher M., Bassett P., et al. Evidence for genetic predisposition to desmoid tumours in familial adenomatous polyposis independent of the germline APC mutation. Gut 2004, 53(12):1832-1836.
173. Bülow S., Björk J., Christensen I., et al. Duodenal adenomatosis in familial adenomatous polyposis. Gut 2004, 53(3):381-386.
174. Davis D., Cohen P. Genitourinary tumors in men with Muir-Torre syndrome. J Am Acad Dermatol 1995, 33:909-912.
175. Vasen H., Wijnen J., Menko F., et al. Cancer risk in families with hereditary nonpolyposis colorectal cancer diagnosed by mutation analysis. Gastroenterology 1996, 110(4):1020-1027.
176. Lin K., Shashidharan M., Thorson A., et al. Cumulative incidence of colorectal and extracolonic cancers in MLH1 and MSH2 mutation carriers of hereditary nonpolyposis colorectal cancer. J Gastrointest Surg 1998, 2:67-71.
177. Aarnio M., Sankila R., Pukkala E., et al. Cancer risk in mutation carriers of DNA-mismatch-repair genes. Int J Cancer 1999, 81(2):214-218.
178. Watson P., Bützow R., Ht L, et al. The clinical features of ovarian cancer in hereditary nonpolyposis colorectal cancer. Gynecol Oncol 2001, 82(2):223-228.
179. Smith R., Cokkinides V., von Eschenbach A., et al. American Cancer Society guidelines for the early detection of cancer. CA Cancer J Clin 2002, 52(1):8-22.